Medical therapy for obesity

Mount Sinai Journal of Medicine

Volumn 77, Issue 5, 2010, Pages 407-417

  Bray, George A ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

adherence; dietary treatments; drug treatments; obesity; positive energy imbalance

Indexed keywords

AMFEBUTAMONE; AMFEPRAMONE; ANTIOBESITY AGENT; BENZPHETAMINE; EXENDIN 4; FENFLURAMINE; FLUOXETINE; LEPTIN; LIRAGLUTIDE; LORCASERIN; METFORMIN; NALTREXONE; OBEZINE; PHENDIMETRAZINE; PHENDIMETRAZINE TARTRATE; PHENTERMINE; PHENTERMINE RESIN; PHENTRIDOL; PLACEBO; PRAMLINTIDE; PRELU 2; SIBUTRAMINE; TESOFENSINE; TETRAHYDROLIPSTATIN; TETRAMINE; TOPIRAMATE; UNCLASSIFIED DRUG; X TROZINE; ZONISAMIDE;

ANOREXIA; AORTA VALVE REGURGITATION; ASTHENIA; BEHAVIOR DISORDER; BLOOD PRESSURE; BODY FAT; CALORIC INTAKE; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DRUG DEPENDENCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; ENERGY EXPENDITURE; FOOD INTAKE; HEADACHE; HUMAN; INSOMNIA; JAUNDICE; LEAN BODY WEIGHT; LOW CALORY DIET; LOW CARBOHYDRATE DIET; LOW FAT DIET; MACRONUTRIENT; MEDITERRANEAN DIET; MENTAL DISEASE; MORNING DOSAGE; NAUSEA; NONHUMAN; OBESITY; PARESTHESIA; PATIENT COMPLIANCE; PROTEIN DIET; PRURITUS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ANTI-OBESITY AGENTS; CALORIC RESTRICTION; HUMANS; OBESITY; WEIGHT LOSS;

EID: 78449243671     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20207     Document Type: Review

References (49)

1. Flegal KM, Carroll MD, Ogden CL, Curtin LR., Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303: 235 - 241.
2. Ogden CL, Carroll MD, Curtin LR, et al., Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA 2010; 303: 242 - 249.
3. Bray GA., The Low-Fructose Approach to Weight Control. Pittsburgh, PA: Dorrance Publishing; 2009.
4. Bray GA., The Metabolic Syndrome and Obesity. Totowa, NJ: Humana Press; 2007.
5. Rosenbaum M, Goldsmith R, Bloomfield D, et al., Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest 2005; 115: 3579 - 3586.
6. Avenell A, Broom J, Brown TJ, et al., Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004; 8: iii - iv, 1-182.
7. Douketis JD, Macie C, Thabane L, Williamson DF., Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond) 2005; 29: 1153 - 1167.
8. Flechtner-Mors M, Ditschuneit HH, Johnson TD, et al., Metabolic and weight loss effects of long-term dietary intervention in obese patients: four-year results. Obes Res 2000; 8: 399 - 402.
9. Pirozzo S, Summerbell C, Cameron C, Glasziou P., Should we recommend low-fat diets for obesity [published correction appears in Obes Rev 2003;4:185]. Obes Rev 2003; 4: 83 - 90.
10. Howard BV, Manson JE, Stefanick ML, et al., Low-fat dietary pattern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial. JAMA 2006; 295: 39 - 49.
11. Thomas DE, Elliott EJ, Baur L., Low glycaemic index or low glycaemic load diets for overweight and obesity. Cochrane Database Syst Rev 2007; 3: CD005105.
12. Paddon-Jones D, Westman E, Mattes RD, et al., Protein, weight management, and satiety. Am J Clin Nutr 2008; 87: 1558S - 1561S.
13. Dansinger ML, Gleason JA, Griffith JL, et al., Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 2005; 293: 43 - 53.
14. Gardner CD, Kiazand A, Alhassan S, et al., Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial [published correction appears in JAMA 2007;298:178]. JAMA 2007; 297: 969 - 977. (Pubitemid 46376751)
15. Davis NJ, Tomuta N, Schechter C, et al., Comparative study of the effects of a 1-year dietary intervention of a low-carbohydrate diet versus a low-fat diet on weight and glycemic control in type 2 diabetes. Diabetes Care 2009; 32: 1147 - 1152.
16. Shai I, Schwarzfuchs D, Henkin Y, et al,; Dietary Intervention Randomized Controlled Trial (DIRECT) Group. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet [published correction appears in N Engl J Med 2009;361:2681]. N Engl J Med 2008; 359: 229 - 241.
17. Sacks FM, Bray GA, Carey VJ, et al., Comparison of weight-loss diets with different compositions of fat, carbohydrate and protein. N Engl J Med 2009; 360: 859 - 873.
18. Alhassan S, Kim S, Bersamin A, et al., Dietary adherence and weight loss success among overweight women: results from the A to Z weight loss study. Int J Obes 2008; 32: 985 - 991.
19. Bray GA, Greenway FL., Pharmacological treatment of the overweight patient. Pharmacol Rev 2007; 59: 151 - 184.
20. Lam DD, Pryzdzial MJ, Ridley SH, et al., Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology 2008; 40: 1323 - 1328.
21. Bray GA, Blackburn GL, Ferguson JM, et al., Sibutramine produces dose-related weight loss. Obes Res 1999; 7: 189 - 198.
22. Rucker D, Padwal R, Li SK, et al., Long term pharmacotherapy for obesity and overweight: updated meta-analysis [published correction appears in BMJ 2007;335. DOI: 10.1136/bmj.39406.519132.AD]. BMJ 2007; 335: 1194 - 1199.
23. Wirth A, Krause J., Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001; 286: 1331 - 1339.
24. Berkowitz RI, Fujioka K, Daniels SR, et al,; Sibutramine Adolescent Study Group. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med 2006; 145: 81 - 90.
25. Wadden TA, Berkowitz RI, Womble LG, et al., Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005; 353: 2111 - 2120.
26. Kim SH, Lee YM, Jee SH, Nam CM., Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res 2003; 11: 1116 - 1123.
27. Hendricks EJ, Rothman RB, Greenway FL., How physician obesity specialists use drugs to treat obesity. Obesity (Silver Spring) 2009; 17: 1730 - 1735.
28. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L., XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients [published correction appears in Diabetes Care 2004;27:856]. Diabetes Care 2004; 27: 155 - 161. (Pubitemid 38196725)
29. Chanoine JP, Hampl S, Jensen C, et al., Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial [published correction appears in JAMA 2005;294:1491]. JAMA 2005; 293: 2873 - 2883.
30. FDA Drug Safety Communication: Completed safety review of Xenical/Alli (orlistat) and severe liver injury. Published May 26, 2010. Accessed June 2, 2010.
31. Wadden TA, Berkowitz RI, Womble LG, et al., Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 2000; 8: 431 - 437.
32. Snow V, Barry P, Fitterman N, et al., Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005; 142: 525 - 531.
33. Edwards CM, Stanley SA, Davis R, et al., Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001; 281: E155 - E161.
34. Amori RE, Lau J, Pittas AG., Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298: 194 - 206.
35. Heine RJ, Van Gaal LF, Johns D, et al., Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143: 559 - 569.
36. Apovian CM, Bergenstal RM, Cuddihy RM, Qu Y, Lenox S, Lewis MS, Glass LC., Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med 2010 May; 123: 468.e9-17.
37. Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD,. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004; 20: 411 - 417.
38. Astrup A, Rössner S, Van Gaal L, et al.,; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study [published correction appears in Lancet 2010;375:984]. Lancet 2009; 374: 1606 - 1616.
39. Buse JB, Rosenstock J, Sesti G, et al.,; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39 - 47.
40. Weintraub M., Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study [published correction appears in Clin Pharmacol Ther 1992;52:323]. Clin Pharmacol Ther 1992; 51: 581 - 585.
41. Connolly HM, Crary JL, McGoon MD, et al., Valvular heart disease associated with fenfluramine-phentermine [published correction appears in N Engl J Med 1997;337:1783]. N Engl J Med 1997; 337: 581 - 588.
42. Greenway FL, Whitehouse MJ, Guttadauria M, et al., Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 2009; 17: 30 - 39.
43. Greenway FL, Dunayvich E, Tollefson G, et al,.; for the NB-201 Study Group. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab 2009; 94: 4898 - 4906.
44. Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, Perri MG, Pi-Sunyer FX, Rock CL, Erickson JS, Maier HN, Kim DD, Dunayevich E,. Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial. Obesity (Silver Spring). 2010 Jun 17. [Epub ahead of print].
45. Heymsfield SB, Greenberg AS, Fujioka K, et al., Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999; 282: 1568 - 1575.
46. Ravussin E, Smith SR, Mitchell JA, et al., Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 2009; 17: 1736 - 1743.
47. Smith SR, Prosser WA, Donahue DJ, et al.,; APD356-004 Study Group. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring) 2009; 17: 494 - 503.
48. Smith SR, Weissman NJ, Anderson CM, et al,.; for the Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363: 245 - 256.
49. Astrup A, Madsbad S, Breum L, et al., Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1906 - 1913.